Skip to content

The Role of Probiotics in the Treatment of Endometriosis (ProMetrioS): a Randomised Double-blinded Placebo-controlled Cross-over Trial

The Role of Probiotics in the Treatment of Endometriosis (ProMetrioS): a Randomised Double-blinded Placebo-controlled Cross-over Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06929364
Acronym
ProMetrioS
Enrollment
40
Registered
2025-04-16
Start date
2024-11-01
Completion date
2025-11-30
Last updated
2025-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis, Probiotics

Keywords

endometriosis, probiotics, microbiome

Brief summary

ProMetrioS is a randomised blinded placebo-controlled cross-over trial investigating the effect of specific multistrain probiotics in patients with endometriosis. The aim of this clinical trial is to determine whether probiotic treatment can significantly modulate gut microbiome composition and functionality in endometriosis patients, specifically parameters associated with the estrobolome.

Detailed description

Patients will be recruited among the outpatient population of the National Center for Endometriosis, Department of Gynecological Surgery and Urology, Gynecology Department, University Hospital Center Zagreb following the inclusion and exclusion criteria. To participate in the study all patients will be required to sign the Informed Consent form. All patients will undergo a complete anamnesis via a digital form to investigate their lifestyle (occupation, stress, diet, physical activity level). The study period will be 6 months: eight weeks on either option (verum/placebo), with an eight week washout period in between. The purpose of the washout period is to allow the gut microbiome to return to baseline. The washout period was determined based on previous gut microbiota studies with a similar design (reference), based on the fact that the gut microbiota can change rapidly (< 7 days) r. The outcome measures (gut microbiome, quality of life) will be assessed in four distinct time points in context of the planned intervention. T1 - before the intervention (start-of-study) T2 - after the first intervention cycle/phase 1 (verum/placebo) of two months T3 - after the wash-out phase of two months T4 - after the second intervention cycle/phase 2 (verum/placebo) of two months (end-of-study) Stool sampling will be performed with the aid of specific kits indepently by the patients. Lifestyle and quality of life will be evaluated by an online form designed specifically for the purpose of this study in Microsoft Office Forms (Microsoft, San Francisco, USA), short Online Form. Through the process of randomization, patients will be allocated to either first receive the verum (probiotic) or the placebo (maltodextrin), and second the placebo or verum inversely. Both patients and researchers involved will be blinded (double-blind study), the patients will be informed that they are going to take a probiotic twice for two months with a two-month time division. The intervention will consist of treatment with a multistrain probiotic formulation (Omni Biotic Stress) and the placebo which is identical in all its characteristics and packaging. Patients will be instructed to consume one sachet a day of each (probiotic) for 8 weeks and to report any symptoms or side effects related to its use. Adherence control will be carried out through the patient's notes on a separate online form provided, and also by checking the number of sachets used. Since this is a cross-over study, data will be compared between time-points T1 and T2, and time-points T3 and T4, with the goal of minimizing the potential effect if we find that the effect of the probiotics lasted longer than eight weeks in those randomized into the intervention arm first.

Interventions

DIETARY_SUPPLEMENTOmni Biotic Stress

Multistrain probiotic formulation (Omni Biotic Stress), 1 sachet daily for 8 weeks

OTHERPlacebo

Inert powder identical in appearance and taste to probiotic, 1 sachet daily for 8 weeks

Sponsors

Clinical Hospital Centre Zagreb
CollaboratorOTHER
The Gut Microbiome Center (Centar za crijevni mikrobiom)
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Masking description

I got error for writing 2 arms and that participants and investigator are masked so I had to adapt it.

Eligibility

Sex/Gender
FEMALE
Age
No minimum to 35 Years
Healthy volunteers
No

Inclusion criteria

Minimum Age: - Maximum Age: 35 Years Sex: Female Gender Based: Ye - only women can participate in this study Accepts Healthy Volunteers: No Inclusion Criteria: * adult subjects with stage III or IV endometriosis diagnosis confirmed by biopsy

Exclusion criteria

* Age \> 35 years * Immunocompromised patients * Patients with chronic inflammatory diseases (e.g., autoimmune disorders) * Pregnancy * Use of supplements and foods with probiotics * Use of immunosuppressant, antibiotic, proton pump inhibitors and corticosteroid drugs * Use of probiotics product less than one month before start of study or during study

Design outcomes

Primary

MeasureTime frameDescription
Change in relative abundance of gut microbial taxa and functional pathways related to the estrobolome in fecal samplesAt baseline, after 8 weeks (end of phase 1), and after 24 weeks (end of phase 2)The primary outcome is the modulation of the gut microbiome. The fecal microbiome, as a genuine proxy of the gut microbiome, will be analyzed. Specific attention will be brought to taxa and metabolic pathways involved in the estrobolome.

Secondary

MeasureTime frameDescription
Change in quality of life measured by EHP-5 questionnaireWeek 1, Week 8, Week 16, Week 24 (6 months)Quality of life will be assessed using the Endometriosis Health Profile-5 (EHP-5) questionnaire at baseline, after each intervention phase, and at the end of the study.
Change in quality of life measured by SEQOL questionnaireWeek 1, Week 8, Week 16, Week 24 (6 months)Quality of life will be assessed using the Stellenbosch Endometriosis Quality of Life (SEQOL) questionnaire at baseline, after each intervention phase, and at the end of the study.

Other

MeasureTime frameDescription
Change in Mediterranean diet adherence (MEDAS score)Week 1, Week 8, Week 16, Week 24 (6 months)Adherence to the Mediterranean diet will be assessed using a validated Mediterranean Diet Adherence Screener (MEDAS) at baseline and after each intervention phase
Change in physical activity levels (IPAQ score)Week 1, Week 8, Week 16, Week 24 (6 months)Physical activity will be assessed using the International Physical Activity Questionnaire (IPAQ) at baseline and after each intervention phase.
Change in perceived stress levels (PSS score)Week 1, Week 8, Week 16, Week 24 (6 months)Perceived stress will be measured using the Perceived Stress Scale (PSS) questionnaire at baseline and after each intervention phase.
Change in sleep quantity (self-reported hours of sleep per night)Week 1, Week 8, Week 16, Week 24 (6 months)Participants will self-report average hours of sleep per night using a standardized sleep questionnaire at baseline and after each intervention phase.

Countries

Croatia

Contacts

Primary ContactIra Renko, MS
ira.renko@gmail.com955096473

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026